Replies to post #92603 on Biotech Values

[biomaven0]

When I originally invested in Ariad last year, I thought it made sense for them to try to retain 100% of 534. I've completely changed my mind on that. True it is well within their financial and other capabilities to take it through to approval in patients who have failed other TKIs. But really to get the maximum value from the drug they need to do some sort of front line trial in high risk patients. That's a much bigger, longer and more expensive trial. The drug also needs to be tried in other indications, and again that is not something they can do unpartnered.

Peter